TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial
Open Access
- 29 January 2023
- journal article
- research article
- Published by Elsevier in JHEP Reports
- Vol. 5 (4) , 100689
Abstract
No abstract availableKeywords
Funding Information
- DHOS
This publication has 14 references indexed in Scilit:
- Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adultsCochrane Database of Systematic Reviews, 2019
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2018
- Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trialThe Lancet Oncology, 2017
- Radiothérapie en conditions stéréotaxiques des tumeurs hépatiques : état de l’artCancer/Radiothérapie, 2017
- Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinomaOncotarget, 2016
- Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular CarcinomaJAMA Oncology, 2015
- Three-dimensional conformal radiotherapy in combination with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma.2014
- Treatment of Intermediate/Advanced Hepatocellular Carcinoma in the Clinic: How Can Outcomes Be Improved?The Oncologist, 2010
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999